In adults with symptomatic NYHA Class II-III obstructive HCM1,2

A DIFFERENCE YOU CAN SEE* AND PATIENTS CAN FEEL

* Echocardiogram assessment of postexercise LVOT gradient.1
Evaluation of symptoms, via NYHA classification.1
  Echo images provided by a US HCP. Actress portrayal.
  It is not known if CAMZYOS is safe and effective in children.

The FDA has updated echo monitoring requirements for eligible patients in the maintenance phase

CAMZYOS is the first and only FDA approved CMI to have a Class 1 recommendation when symptoms persist on a 1L therapy (BB or nondihydropyridine CCB)
Symptoms include effort-related dyspnea or chest pain, and occasionally other exertional symptoms (eg, syncope, near syncope) that are attributed to LVOT obstruction and interfere with everyday activity or quality of life despite beta blocker or nondihydropyridine calcium channel blocker.3
§ Beta blocker or nondihydropyridine calcium channel blocker.
Patient identification

CAMZYOS
Efficacy & Safety

Explore pivotal trial and long-term
efficacy and safety data.1

Patient holding heart

CAMZYOS
Dosing & Administration

Review important dosing and treatment recommendations.1

Checklist and Shield

Start and
Maintain Patients

Resources for appropriate
patients on CAMZYOS.

1L=first-line; ACC=American College of Cardiology; AHA=American Heart Association; CMI=cardiac myosin inhibitor; FDA=US Food and Drug Administration; HCM=hypertrophic cardiomyopathy; LVOT=left ventricular outflow tract; MS=multisociety; NYHA=New York Heart Association.

References:

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X
  3. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250


© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. 
CAMZYOS® and the CAMZYOS and MyCAMZYOS Logos are trademarks of MyoKardia, Inc.

3500-US-2400621   04/25

This site is intended for U.S. Healthcare Professionals only.